Screenshot

Global Conference Brings JGA Families Together, Moves Research Forward

We have had some time to reflect on our time in Boston and our hearts are SO full!

We had 110 families, our entire research team, 30 therapists and doctors from Boston Children’s Hospital and many more join us for our “Together We Stand” JGA Family Conference. Thank you to those of you who traveled from near and far to be there, there’s nothing better than being all together! We hope you left feeling inspired and hopeful.

Screenshot

Click here for a link to the Conference Agenda.
 
If you were unable to attend conference, or if you want to watch the presentations again, here are the YouTube links for all of the 2024 JGA Conference Sessions! Translation services are available via YouTube.

We announced at Conference that Human Clinical Trials will be starting soon. Click here to watch Dr. Wendy Chung’s announcement!

Details for clinical trials are below.

Clinical Fact Sheet

Are you interested in participating in clinical trials? Send an email to joanne.carroll@childrens.harvard.edu and you will be added for the list for consideration.
  
You can read up on all of the research to find a treatment or a cure for Jordan’s Syndrome. Click here to read our 2024 update.
 
We also saw how much you all used the conference Facebook chat and we want to remind you that we have other chats for you to join to stay in the loop. In addition to the Community Chat and the Ask the JGA Team Chat, there is also a Mom’s Group and a Dad’s Group too! Join today! 

We want to thank all of you again for your continued participation and excitement! Together we stand and our future is SO bright! If you have any questions, please don’t hesitate to reach out to any of us here on your JGA Team!
 

Published

August 28, 2024

Share

new-york-gb489d43dd_1280

Research, Research, Research!

Our 2022 Family Conference was incredible not just because we had the opportunity to come together, but because we had to in order to move our research forward. An incredible amount of data was collected.

Sean Calamia, of Dr. Wendy Chung’s team at Columbia University, is one of the many individuals leading the efforts in collecting data for the Jordan’s Guardian Angels Natural History Study. As we wrapped up conference in July, the JGA Team asked Sean to give a rundown on the data collection process and its impact on future clinical trials. Here’s a look:

What is the purpose of collecting clinical data?

1. To better understand and to see the phenotypes, or observable traits, of the genetic disease. If we see a symptom present in greater numbers of people, we have a better idea of what is going on. Conversely, if we see less consistency of a phenotype within the population, then we can readjust.

2. It is required for clinical trials. A few years ago, the FDA made data a necessity for drug development and treatment. Therefore, for us to move forward with gene therapy as well as receive funding and approval for clinical trials that aim to treat a rare disease, we need to collect the data and understand the impact of the genetic misspelling. It could be systematic or molecular and we need to be able to identify what we expect to target and what we expect will change. Since rare diseases have a smaller population of people to collect data from, the FDA even more so wants us to have a good robust cohort for information, which makes it critical for us to do things as soon as possible.

What is the significance of this past Family Conference?

At our July Family Meeting, we got about 50 participants enrolled in the study, which is a great number. Depending on how big of a population is needed for rare diseases, it may be enough to move forward with clinical trials.

What are the immediate next steps after the Family Conference?

We just finished collecting the data and are planning to clean and process it.

What is the timeline for clinical trials?

We first want to make sure we are coming up with multiple avenues of therapy to rescue the rare disease. The scientists and physicians from the conference want to spread out resources across the potential avenues of therapy after the data has been processed.

What is the Natural History data?

It captures what is going on in a patient’s life at this point. For other studies, there is an online Natural History Study which is more of a medical history study that personally accounts for what is going on in the patient’s life. We are developing a new version for approval that we hope to use for Jordan’s Syndrome population within the next six weeks or so.

What are some updates on the Natural History Study?

The data has been collected, which makes up a large part of the work, but will still be continued. Usually, data for the Natural History Study is collected once a year as we do not expect to see significant changes through frequent collections. Since it is a longitudinal study, data will be collected until we reach clinical trials and even past that. With previous findings, we have learned a lot such as that some things are not having the negative impact we hypothesized, which is very good news.

What have been some barriers to data collection?

Funding the trip is a barrier since the data collection occurs at Columbia University and we do not want families to have to financially support the case and fund their trip. There was never a problem in finding participants or getting families motivated as the families have always been unbelievably motivated to contribute.

What is a take-home message for all the families?

While we may not be at the point of clinical trials or have therapies to be tested right now, our current priority is to get all the Natural History data set up for those goals. The best thing you can do right now is to share all the information you have.

##

Thank you to Sean for all of his insight and to our entire research team for their tireless efforts to find a treatment or a cure for Jordan’s Syndrome.

Published

September 21, 2022

Share

Connect With Us

Contact Info

1121 L St, Suite 100, Sacramento, CA 95814

Jordan’s Guardian Angels is a public charity exempt from Federal Income Tax as an organization described in Section 501 (c)(3) of the Internal Revenue Code, EIN 90-1022228. Contributions to Jordan’s Guardian Angels are tax deductible to the fullest extent allowed by law. No goods or services were provided in consideration for the contributions except as reported above.